Organon & Co.
- OGN · NYSE
- Pharmaceutical Preparations
- Jersey City, NJ
- 10,000 employees
- CIK 0001821825
Updated from SEC filings through
Top things to know
Executives
-
Joseph T. Morrissey Jr. Interim CEO 4, 2026-04-02 -
Matthew M. Walsh Chief Financial Officer 4, 2026-04-02 - Matthew Walsh Chief Financial Officer 10-K, 2026-02-24
- Aaron Falcione Chief Human Resources Officer 4, 2026-04-02
- Rachel A. Stahler Chief Information Officer 4, 2026-04-02
- Ferreira Juan Camilo Arjona Head of R&D & CMO 4, 2026-08-12
Organon & Co. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Jersey City, NJ. It trades as OGN on NYSE. Revenue was $6.2B in the fiscal year ending December 31, 2025, -2.9% from the year before. It reported about 10,000 employees. Joseph T. Morrissey Jr. is Interim CEO.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $6.2B 10-K, 2026-02-24 | $6.4B 10-K, 2026-02-24 | $6.3B 10-K, 2026-02-24 | $6.2B 10-K/A, 2025-11-10 | $6.3B 10-K, 2024-02-26 |
| Operating income | Not on file | Not on file | Not on file | Not on file | Not on file |
| SG&A | $1.7B 10-K, 2026-02-24 | $1.8B 10-K, 2026-02-24 | $1.9B 10-K, 2026-02-24 | $1.7B 10-K/A, 2025-11-10 | $1.7B 10-K, 2024-02-26 |
| Net income | $187M 10-K, 2026-02-24 | $864M 10-K, 2026-02-24 | $1.0B 10-K, 2026-02-24 | $917M 10-K/A, 2025-11-10 | $1.4B 10-K, 2024-02-26 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Joseph T. Morrissey Jr. | Interim CEO | 4, 2026-04-02 |
| Matthew M. Walsh | Chief Financial Officer | 4, 2026-04-02 |
| Matthew Walsh | Chief Financial Officer | 10-K, 2026-02-24 |
| Aaron Falcione | Chief Human Resources Officer | 4, 2026-04-02 |
| Rachel A. Stahler | Chief Information Officer | 4, 2026-04-02 |
| Ferreira Juan Camilo Arjona | Head of R&D & CMO | 4, 2026-08-12 |
| Juliana Papa Drinane | Head of Mfg & Supply | 4, 2026-08-05 |
| Lynette Holzbaur | SVP and Corporate Controller | 4/A, 2026-05-07 |
 Carrie S. Cox | Board member (per proxy) bio: Executive Chair of Organon & Co. | DEF 14A, 2026-04-24 |
| Daniel Karp | Executive VP, Corp. Dev. | 4, 2026-04-02 |
| Kirke Weaver | Gen. Counsel & Corp. Secy. | 4, 2026-04-02 |
| Vittorio Nisita | Head of Global Business Svcs | 4, 2026-04-02 |
| Carrie Smith Cox | Executive Chair | 4, 2025-11-13 |
| Cynthia M. Patton | Board member (per proxy) bio: director nominee | DEF 14A, 2026-04-24 |
| Helene Gayle, M.D., M.P.H. | Board member (per proxy) bio: director nominee | DEF 14A, 2026-04-24 |
| R. Alan Ezekowitz, M.D., Ph.D. | Board member (per proxy) bio: director nominee | DEF 14A, 2026-04-24 |
What Organon & Co. does
Organon & Co. (“Organon,” the “Company,” “we,” “our,” or “us”) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across women’s health and general medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 countries and territories.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 262.6 million (as of October 23, 2026) | 10-Q, October 30, 2026 |
|---|---|---|
| Public float | $2.5B (as of June 30, 2025) | 10-K, February 24, 2026 |
| Latest proxy statement | Meeting June 9, 2026 (filed April 24, 2026) | DEF 14A, April 24, 2026 |
| Auditor | PricewaterhouseCoopers LLP (Florham Park, New Jersey) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| August 5, 2026 | Juliana Papa Drinane Head of Mfg & Supply | Sale | 14,761 | $200K | Form 4, August 5, 2026 |
| May 6, 2026 | Lynette Holzbaur SVP and Corporate Controller | Buy | 26,448 | $353K | Form 4, May 7, 2026 |
| November 12, 2025 | Carrie Smith Cox Executive Chair | Buy | 65,400 | $502K | Form 4, November 13, 2025 |
Recent 8-K events
- 8-K filed 2026-10-30
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-07-31
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-07-23
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-07-17
- Item 8.01 Other events
- 8-K filed 2026-06-11
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-04-30
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-27
- Item 1.01 Entry into a material definitive agreement
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-02-20
- Item 8.01 Other events
- 8-K filed 2026-02-12
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-11-10
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
Frequently asked questions about Organon & Co.
- What does Organon & Co. do?
- In its own words, from Item 1 of its 10-K: "Organon & Co. (“Organon,” the “Company,” “we,” “our,” or “us”) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across women’s health and general medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 countries and territories."
- What is Organon & Co.'s revenue?
- $6.2B for the fiscal year ending December 31, 2025, from its 10-K filed February 24, 2026.
- Is Organon & Co. profitable?
- Organon & Co. reported net income of $187M for the fiscal year ending December 31, 2025.
- How many employees does Organon & Co. have?
- About 10,000 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Organon & Co.?
- Joseph T. Morrissey Jr., Interim CEO, as named in a 4 filed April 2, 2026.
- Who is the CFO of Organon & Co.?
- Matthew M. Walsh, Chief Financial Officer, as named in a 4 filed April 2, 2026.
- Where is Organon & Co. headquartered?
- Jersey City, NJ.
- What is Organon & Co.'s stock ticker?
- OGN on NYSE.
- What industry is Organon & Co. in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Organon & Co.'s website?
- organon.com.
- When does Organon & Co. report earnings next?
- November 9, 2026. Source: pg_future_events.
- Is Organon & Co. a public company?
- Yes. Organon & Co. files with the SEC under CIK 0001821825 and trades as OGN.
- Who audits Organon & Co.?
- PricewaterhouseCoopers LLP, Florham Park, New Jersey, as named in its latest annual report (10-K).
- How many shares of Organon & Co. are outstanding?
- 262.6 million shares as of October 23, 2026, from its 10-Q filed October 30, 2026.
- What is Organon & Co.'s public float?
- $2.5B as of June 30, 2025, as reported on the cover of its 10-K filed February 24, 2026.
- When is Organon & Co.'s annual shareholder meeting?
- June 9, 2026, per its proxy statement (DEF 14A) filed April 24, 2026.
- Have Organon & Co. insiders traded stock recently?
- Since November 12, 2025, officers and directors reported 1 open-market sale worth about $200K and 2 purchases worth about $855K on Forms 4 and 5. The most recent: Juliana Papa Drinane (Head of Mfg & Supply) sold 14,761 shares on August 5, 2026.